XML 57 R46.htm IDEA: XBRL DOCUMENT v3.25.1

Operating Segments and Related Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Company's Operating Segments

Financial information, including revenue and expenses, with respect to the Company’s operating segments, is as follows (in millions):

						Three Months Ended March 31, 2025
						Infrastructure						Life Sciences						Spectrum						Non-Operating Corporate						Other and Eliminations						INNOVATE
Revenue						$	264.9					$	3.1					$	6.2					$	—											$	274.2
Cost of revenue						223.5						2.3						2.9						—						—						228.7
Selling, general and administrative expenses						29.3						3.7						1.9						2.9						—						37.8
Depreciation and amortization						3.1						0.1						1.2						—						—						4.4
Other operating income						(0.1)						—						—						—						—						(0.1)
Income (loss) from operations						$	9.1					$	(3.0)					$	0.2					$	(2.9)					$	—					$	3.4
Other data:
Capital expenditures (1)						$	4.1					$	0.1					$	0.5					$	—					$	—					$	4.7
Investments (2)						$	—					$	1.8					$	—					$	2.3					$	—					$	4.1
Total assets						$	671.9					$	11.7					$	178.3					$	6.1					$	—					$	868.0

(1) Capital expenditures reflect cash expenditures for the three months ended March 31, 2025.

(2) The Company's equity method investments in the Life Sciences segment totaled $0.9 million as of March 31, 2025.

						Three Months Ended March 31, 2024
						Infrastructure						Life Sciences						Spectrum						Non-Operating Corporate						Other and Eliminations						INNOVATE
Revenue						$	307.9					$	1.0					$	6.3					$	—					$	—					$	315.2
Cost of revenue						263.1						0.6						2.9						—						—						266.6
Selling, general and administrative expenses						30.9						3.5						1.9						3.2						—						39.5
Depreciation and amortization						3.0						0.1						1.3						—						—						4.4
Other operating loss (1)						1.6						—						—						0.3						—						1.9
Income (loss) from operations						$	9.3					$	(3.2)					$	0.2					$	(3.5)					$	—					$	2.8
Other data:
Capital expenditures (2)						$	5.2					$	0.1					$	0.3					$	—					$	—					$	5.6
						December 31, 2024
						Infrastructure						Life Sciences						Spectrum						Non-Operating Corporate						Other and Eliminations						INNOVATE
Investments (3)						$	—					$	1.8					$	—					$	1.8					$	—					$	3.6
Total assets						$	683.6					$	11.9					$	178.9					$	16.7					$	—					$	891.1

(1) Other operating loss for the three months ended March 31, 2024, primarily consisted of a loss on disposal related to a plant closure at our Infrastructure segment.

(2) Capital expenditures reflect cash expenditures for the three months ended March 31, 2024.

(3) The Company's equity method investments in the Life Sciences segment totaled $0.9 million as of December 31, 2024.

												Three Months Ended March 31,
																		2025						2024
Reconciliation of the consolidated segment income from operations to consolidated loss from operations before income taxes:
Income from operations																		$	3.4					$	2.8
Interest expense																		(20.2)						(17.2)
Loss from equity investees																		(5.9)						(1.2)
Other income (expense), net																		4.0						(1.2)
Loss from operations before income taxes																		$	(18.7)					$	(16.8)

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration